Pfizer pairs up with Adaptive Bio; Woodford calls for GSK breakup;

@FierceBiotech: Zymeworks bags a $61.5M round, with a merger on tap and an IPO in view. Report | Follow @FierceBiotech

@JohnCFierce: Mylan bets $245M on a 50/50 biosimilar development pact with Momenta. Story | Follow @JohnCFierce

@DamianFierce: I feel like Bill Gross trying to get people to rise up against Bill Gross. More | Follow @DamianFierce

> Former Melinta Therapeutics CEO Mary Szela is taking the CEO spot at Aegerion Pharmaceuticals ($AEGR), taking over for former chief Marc Beer, who resigned last year. News

> Pfizer ($PFE) is partnering with Adaptive Biotechnologies in hopes of using genomic sequencing to better match cancer patients to in-development immunotherapies. More

> U.K. biotech investor Neil Woodford has again called for GlaxoSmithKline ($GSK) to break up its business. Story

Medical Device News

@FierceMedDev: Bard to close Minnesota plant, eliminating 185 jobs. Article | Follow @FierceMedDev

@EmilyWFierce: $GSK halting speakers fees for docs in an effort to clean up its tarnished rep. More from the FT | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: NEA partner outlines challenging med tech VC landscape heading into 2016. Article | Follow @VarunSaxena2

> Sony, Fujifilm reportedly considering bidding for Toshiba's $3B+ imaging device unit. More

> Validic app enables remote medical device data capture via smartphone camera. Report

> Michael J. Fox Foundation and Cynapsus team for wearable device study for Parkinson's. Article

Pharma News

@FiercePharma: China Animal Healthcare creates embarrassment for stakeholder Lilly. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. More | Follow @EricPFierce

@CarlyHFierce: If hospitalized Valeant chief makes an exit, it'll be without a golden parachute. More | Follow @CarlyHFierce

> U.K. investor Woodford calls again for breakup of 'complicated' GSK. Story

> Wait for it--Shire could finally announce $32.5B Baxalta deal by Monday. Item

> Aegerion names Mary Szela CEO to replace controversial, and overly talkative, Marc Beer. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.